By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Chemin Messidor 5-7
Case Postale 5911
Lausanne    CH - 1002  Switzerland
Phone: 41-21-321-0111 Fax: 41-21-321-0169


Company News
Debiopharm Awarded $2.6 Million Grant From CARB-X To Support Development Of Debio 1453 To Fight Drug Resistant Gonorrhea 7/25/2017 8:53:31 AM
Arbor Pharma And Debiopharm Announce U.S. FDA Approval For Triptodur, Triptorelin 6-Month Formulation, In The Treatment Of Central Precocious Puberty (CPP) 6/30/2017 6:38:36 AM
Almac Discovery And Debiopharm Announce A Licensing Agreement For The Development Of A Novel Wee-1 Inhibitor 6/20/2017 9:36:32 AM
Debiopharm Announces Completion Of Enrollment In Phase I/II Clinical Trial With Debio 1143 In SCCHN 6/15/2017 7:43:57 AM
Debiopharm Announces Results From Phase I Dose-Escalation Study Of Debio 1347/CH5183284 6/1/2017 9:26:09 AM
Debiopharm Enters The Field Of Antibody-Drug Conjugates Through Acquisition Of Phase II Asset From ImmunoGen (IMGN) 5/24/2017 8:47:20 AM
BC Platforms Closes USD $10 Million Series B Financing Led By Debiopharm And Tesi To Accelerate Knowledge Platform Development 5/9/2017 9:02:50 AM
Debiopharm Uses Cutting-Edge ClinTrial App Mobile Application From ClinOne In Clinical Study 3/23/2017 12:04:24 PM
Debiopharm Innovation Fund: The New Name And Investment Strategy Of Debiopharm Diagnostics 3/7/2017 7:33:38 AM
Debiopharm Release: Biopharma Announces Positive Phase 2 Clinical Trial With Debio 1450 In ABSSSI Patients 1/10/2017 10:01:18 AM